SCHEMBL3198471

SCHEMBL3198471

CC(C)n1cc(Cc2cc3cccc(-c4cccc(C(=O)NCCO)c4)c3s2)ccc1=O

nearest known ligand 0.62

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR52 Q9Y2T5 17/20 0.62
PDE7A Q13946 1/20 0.42
FYN P06241 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13489559 0.89 GPR52 (0.65) GPR52PDE7AFYN
SCHEMBL3218822 0.84 GPR52 (0.67) GPR52
SCHEMBL3215801 0.83 GPR52 (0.45) GPR52
SCHEMBL3207171 0.81 GPR52 (0.68) GPR52FYN
SCHEMBL3207002 0.80 GPR52 (0.60) GPR52FYN
SCHEMBL3207357 0.80 GPR52 (0.62) GPR52PDE7AFYN
SCHEMBL3206759 0.79 GPR52 (0.63) GPR52FYN
SCHEMBL7947953 0.79 GPR52 (0.40) GPR52PDE7AFYN
SCHEMBL1856725 0.78 GPR52 (0.69) GPR52PDE7A
SCHEMBL1856933 0.78 GPR52 (0.57) GPR52FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 GPR52 1/4885PDE7A 1123/4885FYN 1500/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.